MilliporeSigma has launched its Plug & Play Upstream Development Service to help emerging biotech and start-up companies optimize the cost and speed of advancing their molecule to the clinical stage.
           
Eliminating the need to work with multiple vendors for upstream development, the new service aims to reduce bottlenecks, lowering time to clinic by two months. The Plug & Play Upstream Development Service includes cell line development, standard analytics, early material from stable pool, and study and clone selection.
           
For customers looking to progress at a faster speed, MilliporeSigma offers its fast-track process by running process development and clone development steps in parallel, working to balance speed and risk without sacrificing quality. According to the company, its automated mini-pool approach allows it to more efficiently generate early material for process development, reducing the timeline by 10 weeks for the first pharmacodynamic experiment at the preclinical stage.
           
Optional, add-on plug and play services are available, including off-the-shelf media and feed screening, analytical method development, complete analytics, GMP master cell bank (MCB) and cell bank characterization, and MCB storage.
           
Customers also have the option for MilliporeSigma’s BioReliance Product Characterization team to synthesize data from multiple analytical and bioanalytical methods to help reveal the true identity of the product, ensuring the biotherapy’s safety, purity and potency with off-the-shelf mAb-based assay packages or a custom assay tailored for the biologic.